CN111773237A - Turkey knotweed polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines - Google Patents
Turkey knotweed polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines Download PDFInfo
- Publication number
- CN111773237A CN111773237A CN201910268464.3A CN201910268464A CN111773237A CN 111773237 A CN111773237 A CN 111773237A CN 201910268464 A CN201910268464 A CN 201910268464A CN 111773237 A CN111773237 A CN 111773237A
- Authority
- CN
- China
- Prior art keywords
- pcp
- polysaccharide
- galactose
- arabinose
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 66
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 64
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 64
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 229940079593 drug Drugs 0.000 title abstract description 11
- 235000006386 Polygonum aviculare Nutrition 0.000 title abstract description 6
- 230000002391 anti-complement effect Effects 0.000 title abstract description 6
- 108010008730 anticomplement Proteins 0.000 title abstract description 6
- 241001377695 Polygonum arenastrum Species 0.000 title description 4
- 240000003109 Persicaria chinensis Species 0.000 claims abstract description 16
- 229930182830 galactose Natural products 0.000 claims description 28
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 25
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 22
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 14
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 13
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 13
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 13
- 150000002772 monosaccharides Chemical class 0.000 claims description 12
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 11
- 229940097043 glucuronic acid Drugs 0.000 claims description 10
- 238000004192 high performance gel permeation chromatography Methods 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 230000003171 anti-complementary effect Effects 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 claims description 3
- 241000207925 Leonurus Species 0.000 claims description 3
- 239000012506 Sephacryl® Substances 0.000 claims description 3
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 claims description 3
- 238000005227 gel permeation chromatography Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- -1 Turkey red polysaccharides Chemical class 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 claims 3
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 4
- 230000024203 complement activation Effects 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 241001558441 Persicaria decipiens Species 0.000 abstract 2
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 206010018910 Haemolysis Diseases 0.000 description 9
- 230000008588 hemolysis Effects 0.000 description 9
- 230000037361 pathway Effects 0.000 description 8
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 7
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000219050 Polygonaceae Species 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007982 barbital buffer Substances 0.000 description 3
- 239000004074 complement inhibitor Substances 0.000 description 3
- 230000004154 complement system Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124073 Complement inhibitor Drugs 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000205407 Polygonum Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- UBXYXCRCOKCZIT-UHFFFAOYSA-N biphenyl-3-ol Chemical group OC1=CC=CC(C=2C=CC=CC=2)=C1 UBXYXCRCOKCZIT-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000031978 negative regulation of complement activation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000012354 sodium borodeuteride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Sustainable Development (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, and relates to active polysaccharide in Chinese knotweed herb, a preparation method thereof and application thereof in preparation of anticomplement medicines. The invention separates active polysaccharides PCP-B2 and PCP-B3 from Chinese medicine herb knotweed for clearing heat and removing toxicity, and experiments prove that the polysaccharides PCP-B2 and PCP-B3 of the herb knotweed have obvious inhibition effect on complement activation and can be further used as active ingredients to prepare novel anticomplement medicines.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and relates to polysaccharides, in particular to two natural anticomplementary active polysaccharides in Chinese knotweed herb, a preparation method thereof and application thereof in preparing anticomplementary medicines.
Background
The complement system is an important component of the human immune system, and its normal activation plays an important role in exterminating foreign microorganisms, removing damaged or dead cells and tissues in the body, and maintaining the balance of the body. However, in some cases, abnormal activation of the complement system causes an excessive reaction of the human immune system, resulting in damage to normal tissues of the human body itself, such as rheumatoid and rheumatoid arthritis, Systemic Lupus Erythematosus (SLE), Acute Respiratory Distress Syndrome (ARDS), acute pneumonia caused by influenza virus, and severe atypical pneumonia (SARS). It follows that excessive complement system activation is one of the important conditions in the above-mentioned diseases.
At present, the traditional immunosuppressant drugs such as glucocorticoid, cyclophosphamide, methotrexate and the like which are widely used clinically have a certain treatment effect on diseases related to excessive complement activation, but because the drugs are not specific complement inhibitors, the long-term use of the drugs can reduce the defense function of the body, so that the anti-infection capability of the human body is reduced, and even various complications and side effects are generated. Under the circumstances, the search for a novel complement inhibitor with high efficiency, specificity and low toxicity is an urgent need for clinical treatment of the diseases.
The botanical drugs, especially the heat-clearing and detoxifying traditional Chinese medicines, have widely components with anticomplementary activity, and the traditional Chinese medicine resources in China are rich, so that many traditional Chinese medicines have obvious regulating effect on the immune system, and are valuable resources for researching anticomplementary medicines. During the period of curing SARS, the Chinese medicine and Chinese medicine can obtain obvious effect for preventing and curing SARS. Therefore, the search for novel and efficient anticomplement substances from medicinal plants is of great significance.
Herb of Chinese knotweed (Polygonum chinense Linn.) is the dry aerial part of herb of Polygonum of Polygonaceae (Polygonaceae), is pungent, bitter and cool in nature, and is mainly produced in Guangxi, Guangdong, Yunnan provinces and other places in south China. Has the functions of clearing away heat and toxic material, eliminating dampness, relieving itching, improving eyesight, eliminating nebula, etc. The herb of Huocheng is a common medicine in the south of China for folks and is mainly used for treating symptoms such as diarrhea, swollen and sore throat, hepatitis, acute mastitis and pain knot. Modern pharmacological studies show that the Chinese knotweed has the effects of resisting inflammation, bacteria, viruses, oxidation, central inhibition, smooth muscle and skeletal muscle influence and the like. Researches find that the crude polysaccharide of the Chinese knotweed herb has obvious anti-complement activity and has obvious treatment effect on mice with acute lung injury induced by viruses. However, the report of the isolation and preparation of anticomplementary active homogeneous polysaccharide in the pyrocarbon mother is not found.
Disclosure of Invention
The invention aims to provide active ingredients with an anticomplementary effect in natural medicines, and particularly relates to two Chinese knotweed polysaccharides (PCP-B2 and PCP-B3), a preparation method thereof and application thereof in preparing a complement inhibition medicine.
The invention separates two polysaccharides obtained by water extracts of Chinese herb knotweed which is a common heat-clearing and detoxifying traditional Chinese medicine, and in vitro experiments prove that the two polysaccharides both have anticomplementary activity and can be developed as a complement inhibitor.
In the invention, the traditional Chinese medicine Chinese knotweed is dry overground part of Chinese knotweed of Polygonum of Polygonaceae.
The structural characteristics of the leonurus igniarius polysaccharides PCP-B2 and PCP-B3 are described as follows:
(1) the structure of the Chinese knotweed polysaccharide PCP-B2 is characterized in that the molecular weight of the polysaccharide consisting of seven monosaccharides is about 3.2 × 105Da; total sugar content about 95%; the protein content is lower than 2%; the uronic acid content is about 15%. The monosaccharide molar ratio is mannose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose which are 3.7: 5.7: 2.8: 2.1: 1.8: 10.5: 6.7. The connection mode mainly comprises terminal galactose, terminal arabinose, 1, 5-connection arabinose, 1, 4-connection galacturonic acid, 1, 4-connection glucuronic acid and 1, 3, 4, 6-connection galactose. .
(2) The structure of the Chinese knotweed polysaccharide PCP-B3 is characterized in that the molecular weight of the polysaccharide consisting of seven monosaccharides is about 3.0 × 105Da; total sugar content about 91%; the protein content is lower than 2%; the uronic acid content is about 10%. The molar ratio of the monosaccharide is mannose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose which are 2.9: 3.0: 1.9: 1.4: 2.2: 13.4: 8.5. The connection mode mainly comprises the end group connected galactose, the end group connected arabinose, the end group connected rhamnose, the end group connected mannose, 1, 5-connected arabinose, 1, 4-connected galactose, 1, 3-connected arabinose and 1, 6-connected galactose. .
The Chinese knotweed polysaccharide PCP-B2 and PCP-B3 are prepared by the following method:
extracting the Chinese knotweed with 95% ethanol, filtering, drying the residue, extracting with hot water, filtering the extract, concentrating, adding 4 times of absolute ethanol, standing, centrifuging to remove the supernatant, dissolving the precipitate with water again, removing protein with trichloroacetic acid, centrifuging, adjusting the supernatant to neutral, concentrating, dialyzing, and freeze-drying to obtain crude polysaccharide. Dissolving the crude polysaccharide with distilled water, and performing primary separation by using DEAE-cellulose column chromatography. Eluting with distilled water, 0.4, 0.8, 1.2 and 2.0mol/L NaCl solution, collecting fractions, concentrating, dialyzing (molecular weight cut-off of 14000Da) and lyophilizing to obtain 5 secondary components: PCP-A1, PCP-A2, PCP-A3, PCP-A4, and PCP-A5.
Dissolving each secondary component in proper amount of deionized water, centrifuging, separating the supernatant with gel chromatography Sephacryl S-300, and collecting each fraction. Detecting the absorbance value at 488nm (after color development by sulfuric acid-phenol method) by a separating tube, combining the flow components, concentrating and freeze-drying to obtain the homogeneous polysaccharide.
In vitro tests prove that the Chinese knotweed polysaccharide PCP-B2 and PCP-B3 have obvious inhibition on cell hemolysis caused by activation of the classical pathway and the alternative pathway of complement, namely have obvious anticomplementary effect.
CH of Turkey knotweed polysaccharides PCP-B2 and PCP-B350Values (concentration of test sample required for 50% inhibition of hemolysis by the classical pathway) were about 531.5. + -. 1.5. mu.g/mL and 47.6. + -. 3.8. mu.g/mL, respectively; AP of PCP-B2 and PCP-B350The values (concentration of test sample required for 50% inhibition of hemolysis by the alternative pathway) were about 641.8. + -. 6.4. mu.g/mL and 81.9. + -. 4.3. mu.g/mL, respectively.
Drawings
FIG. 1 shows HPGPC chromatograms of PCP-B2(A) and PCP-B3(B), wherein,
TSK-GEL GMPWXLgel column (300 × 7.6.6 mm), eluent distilled water, and flow rate of 0.8 ml/min.
Detailed Description
Example 1 preparation of the Turkey polysaccharides PCP-B2 and PCP-B3.
Pulverizing 6kg of Chinese knotweed herb, extracting with 95% ethanol, filtering, extracting the residue with water solution for 3 times, concentrating, centrifuging, adding 4 times of anhydrous ethanol into the supernatant, standing, centrifuging to remove the supernatant, redissolving the precipitate with water, recovering under reduced pressure, and removing ethanol; removing free protein from the compound solution with 10% trichloroacetic acid, centrifuging, adjusting the supernatant to neutral, dialyzing, concentrating, and freeze drying to obtain crude polysaccharide. 60g of crude polysaccharide is dissolved in distilled water, centrifuged, and the supernatant is subjected to preliminary separation by DEAE-cellulose column chromatography. Eluting with distilled water and NaCl solution of 0.4, 0.8, 1.2, 2.0mol/L, eluting with volume more than 2 times column volume (about 10L), flow rate 25 mL/min, collecting each fraction, and detecting absorbance value at 488nm (after sulfuric acid-phenol method color development) with separate tubes. According to the chromogenic reaction of sugar and the result of HPGPC detection, the fractions are combined, concentrated, dialyzed and freeze-dried to obtain 5 secondary components: PCP-A1, PCP-A2, PCP-A3, PCP-A4, and PCP-A5.
Dissolving PCP-A2(7.1g) in distilled water, centrifuging, and collecting supernatantTMSeparating with S-300 gel chromatographic column, eluting with distilled water at flow rate of 0.35mL/min, and collecting each fraction. Detecting absorbance value at 488nm (after color development by sulfuric acid-phenol method) with a tube, mixing the same fractions according to HPGPC detection result, concentrating, dialyzing, and freeze-drying to obtain homogeneous polysaccharide PCP-B2(200 mg).
Dissolving PCP-A3(2.6g) in distilled water, centrifuging, and separating supernatant with SephacrylTMSeparating by S-300 chromatography, eluting with distilled water at flow rate of 0.35mL/min, and collecting each fraction. Detecting absorbance value at 488nm (after color development by sulfuric acid-phenol method) with a tube, combining the same fractions according to HPGPC detection result, concentrating, dialyzing, and freeze-drying to obtain polysaccharide PCP-B3(220 mg).
Detecting by High Performance Gel Permeation Chromatography (HPGPC) that the polysaccharide PCP-B2 is uniform component and PCP-B3 is relatively uniform component.
Example 2 structural characterization of the Turkey polysaccharide (PCP-B2 and PCP-B3).
(1) Determination of molecular weight
The method adopts High Performance Gel Permeation Chromatography (HPGPC) to measure the relative molecular force of polysaccharide sample, and adopts the basic principle that homogeneous polysaccharide forms symmetrical chromatographic peak through gel permeation chromatography, the peak-off time is related to molecular weight, and the calculation is carried out according to standard curve obtained from known molecular weight.
Chromatographic conditions are as follows: by TSK GMPWXLThe gel column was used for separation at a flow rate of 0.8mg/mL and a sample volume of 20. mu.L, with ultrapure water as the mobile phase, at a column temperature of 25 ℃ and an Evaporative Light Scattering Detector (ELSD).
The experimental method comprises the following steps: accurately weighing homogeneous polysaccharide and dextran series standard 2.0mg each, preparing into 2.0mg/mL solution with distilled water, detecting with 0.45 micrometer microporous membrane before sample injection, recording retention time, and using standard polysaccharidePlotting the logarithmic value of molecular weight (Lg) as ordinate and retention time as abscissa to obtain standard curve, obtaining corresponding linear regression equation, calculating the relative molecular weight of polysaccharide, the relative molecular weights of PCP-B2 and PCP-B3 are 3.2 × 105Da and 3.0 × 105Da。
(2) Determination of total sugar, uronic acid, protein and sulfate group content
The total sugar content of PCP-B2 is 94.83 + -3.58% and PCP-B3 is 91.21 + -4.39% by sulfuric acid-phenol method.
The content of uronic acid detected by m-hydroxy biphenyl method is 14.51 + -0.85% PCP-B2 uronic acid, and 10.10 + -0.32% PCP-B3 uronic acid.
Protein content determination by Coomassie Brilliant blue method: the content of PCP-B2 protein is 1.46 +/-0.05%, and the content of PCP-B3 protein is 1.82 +/-0.02%.
(3) Monosaccharide composition analysis
And respectively reacting the PCP-B2 and the PCP-B3 with 2mol/L TFA at 110 ℃ for 5h to perform complete acid hydrolysis, reacting the obtained complete acid hydrolysis product with 0.5mol/L PMP methanol solution under the alkaline condition of concentrated ammonia water for 150min to perform derivatization, and performing LC-MS analysis on the derivatized product.
PCP-B2 is a polysaccharide mainly composed of seven monosaccharides in the molar ratio of mannose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose (3.7: 5.7: 2.8: 2.1: 1.8: 10.5: 6.7).
PCP-B3 is a polysaccharide mainly composed of seven monosaccharides, wherein the molar ratio of the monosaccharides is mannose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose is 2.9: 3.0: 1.9: 1.4: 2.2: 13.4: 8.5.
(4) Methylation analysis
PCP-B2 and PCP-B3 contain uronic acid, and CMC-NaBH is first applied4After reduction, the polysaccharides are methylated by the modified Hakomori method, and the methylated products are perhydrolyzed with 2mol/L TFA, NaBD4Reduction and acetylation of acetic anhydride to produce a partially methylated alditol acetate derivative, followed by GC-MS analysis.
The methylation result of PCP-B2 shows that the structure contains: end-linked arabinose, end-linked rhamnose, 1, 3-linked arabinose, 1, 5-linked arabinose, 1, 4-linked rhamnose, 1, 2, 4-linked rhamnose, end-linked mannose, 1, 2-linked mannose, end-linked galactose, 1, 3-linked glucose, 1, 4-linked glucuronic acid, 1, 4-linked galacturonic acid, 1, 3, 4-linked galactose, 1, 2, 6-linked galactose, 1, 3, 4, 6-linked galactose, in a molar ratio of 4.4: 1.9: 0.8: 2.6: 1.2: 1.6: 1.2: 1.7: 3.8: 2.0: 2.9: 2.5: 1.3: 1.2: 1.3: 2.9. Wherein, the main components are terminal galactose, terminal arabinose, 1, 5-linked arabinose, 1, 4-linked galacturonic acid, 1, 4-linked glucuronic acid and 1, 3, 4, 6-linked galactose.
The methylation result of PCP-B3 shows that the structure contains: the end group is connected with arabinose, the end group is connected with rhamnose, 1, 3-connected arabinose, 1, 5-connected arabinose, the end group is connected with mannose, the end group is connected with galactose, the end group is connected with glucose, 1, 4-connected galactose, 1, 6-connected glucose, 1, 6-connected galactose, 1, 3, 6-connected galactose and 1, 3, 4, 6-connected galactose, and the molar ratio is 4.8: 2.6: 1.6: 2.7: 2.8: 8.2: 1.8: 2.8: 1.4: 1.6: 0.5: 0.7. Wherein, the main components are galactose connected with an end group, arabinose connected with an end group, rhamnose connected with an end group, mannose connected with an end group, 1, 5-arabinose connected, 1, 4-galactose connected, 1, 3-arabinose connected and 1, 6-galactose connected.
Example 3 classical pathway complement inhibition assay
Serum of 3-month-old guinea pig was sensitized with 2% sheep red blood cells, and diluted 1: 80 with barbital buffer as the complement source for this classical pathway. Diluting rabbit anti-sheep erythrocyte antibody with Barbital Buffer Solution (BBS) to 1: 1000 as hemolysin; sheep Red Blood Cells (SRBC) preserved in Alsever fluid were configured as 2% SRBC. Polysaccharide 3mg is precisely weighed, added with BBS buffer solution for dissolution, and diluted into 8 concentrations in a double way. 200. mu.L of polysaccharide solution at different concentrations was mixed with 200. mu.L of complement diluted 1: 100 andadding 100 μ L hemolysin (1: 1000) and 100 μ L2% SRBC in sequence, placing in water bath at 37 deg.C for 30min, placing in low temperature high speed centrifuge, and centrifuging at 4 deg.C and 5000rpm for 10 min. mu.L of supernatant was taken from each tube in a 96-well plate and absorbance was measured at 405 nm. The experiment was performed with a polysaccharide control group (200. mu.L of polysaccharide at the corresponding concentration plus 400. mu.L of LBBS buffer), a complement control group (200. mu.L of BBS buffer instead of polysaccharide), and a whole blood-lysed group (100. mu.L of 2% SRBC in 500. mu.L of triple distilled water). And subtracting the absorbance value of the polysaccharide group of each concentration from the absorbance value of the corresponding polysaccharide control group to calculate the hemolysis inhibition rate. The logarithm of the polysaccharide concentration was plotted on the X-axis and the inhibition rate of hemolysis was plotted on the Y-axis, and the Concentration (CH) of the sample required for 50% inhibition of hemolysis was calculated from the obtained fitted curve50Value). Heparin was used as a positive control, and the results showed that both pyrocarbon polysaccharides had significant inhibitory activity on classical complement pathway activation (see table 1).
Example 4 alternative pathway complement inhibition assay
Serum of healthy adult male volunteers was extracted with EGTA-BBS buffer (barbital buffer, pH 7.4, containing 5mM MG)2+And 8mM EGTA) diluted 1: 10 as a source of complement for the alternative pathway. Rabbit red blood cells stored in 3.8% sodium citrate solution were made up in EGTA-BBS buffer to 0.5% rabbit red blood cells. Polysaccharide was precisely weighed at about 3mg, and EGTA-BBS buffer was added to the solution to be diluted to 8 concentrations. Pre-incubating 150 μ L of polysaccharide solution with different concentrations and 150 μ L of complement at a ratio of 1: 8 at 37 deg.C for 10min, adding 200 μ L of 0.5% rabbit red blood cell, placing in water bath at 37 deg.C for 30min, placing in low-temperature high-speed centrifuge, and centrifuging at 5000rpm and 4 deg.C for 10 min. mu.L of supernatant was taken from each tube in a 96-well plate and absorbance was measured at 405 nm. The experiment was performed in parallel with a polysaccharide control group (150. mu.L of polysaccharide solution of corresponding concentration plus 350. mu.L of EGTA-BBS buffer), a complement control group (150. mu.L of GTA-BBS buffer instead of the polysaccharide solution), and a whole blood group (200. mu.L of 0.5% rabbit red blood cells in 300. mu.L of triple distilled water). And subtracting the absorbance value of the polysaccharide group of each concentration from the absorbance value of the corresponding polysaccharide control group to calculate the hemolysis inhibition rate. The logarithm of the polysaccharide concentration was plotted on the X-axis and the inhibition rate of hemolysis was plotted on the Y-axis, and the concentration of the sample required for 50% inhibition of hemolysis (AP) was calculated from the obtained fitted curve50Value). To be provided withHeparin was used as a positive control and the results are shown in table 1.
TABLE 1 inhibition of complement activation by two pyrocarbon polysaccharides
CH50And AP50The values are expressed as: mean ± SD (n ═ 3).
Claims (4)
1. Use of Chinese knotweed polysaccharide in preparation of body-tonifying inhibiting medicine; the pyrocarbon polysaccharides are PCP-B2 and PCP-B3.
2. The use according to claim 1, wherein the leonurus igniarius polysaccharide PCP-B2 is structurally characterized by:
polysaccharides composed of seven monosaccharides and having a molecular weight of about 3.2 × 105Da; total sugar content about 95%; the protein content is lower than 2%; uronic acid content of about 15%; the monosaccharide molar ratio is mannose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose which are 3.7: 5.7: 2.8: 2.1: 1.8: 10.5: 6.7; the connection mode mainly comprises terminal galactose, terminal arabinose, 1, 5-connection arabinose, 1, 4-connection galacturonic acid, 1, 4-connection glucuronic acid and 1, 3, 4, 6-connection galactose.
3. The use of claim 1, wherein the structural feature of the Turkey polysaccharide PCP-B3 is a polysaccharide of seven monosaccharides, with a molecular weight of about 3.0 × 105Da; total sugar content about 91%; the protein content is lower than 2%; uronic acid content of about 10%; the monosaccharide molar ratio is mannose, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose which are 2.9: 3.0: 1.9: 1.4: 2.2: 13.4: 8.5; the connection mode mainly comprises the end group connected galactose, the end group connected arabinose, the end group connected rhamnose, the end group connected mannose, 1, 5-connected arabinose, 1, 4-connected galactose, 1, 3-connected arabinose and 1, 6-connected galactose.
4. The leonurus ignatii polysaccharide of claim 1, which is prepared by the steps of:
extracting Chinese medicine herb Polygoni chinensis with ethanol, filtering, extracting dregs of a decoction with hot water, filtering, concentrating, centrifuging, adding a proper amount of ethanol into supernate, keeping the ethanol at the final concentration of 75-85%, centrifuging to remove the supernate, re-dissolving the precipitate with water, and removing free protein to obtain crude polysaccharide; dissolving crude polysaccharide in water, separating by DEAE-cellulose chromatography, eluting with distilled water and 0.4, 0.8, 1.2 and 2.0mol/L NaCl solution, and mixing the same polysaccharide components according to effluent saccharide color reaction and HPGPC detection result; the 2 polysaccharide fractions eluted with 0.4 and 0.8mol/L NaCl solution were further purified by Sephacryl S-300 gel chromatography, eluted with distilled water, and the same fractions were combined according to the results of glycochromogen reaction and HPGPC detection, and subjected to detection of anticomplementary activity to give Turkey red polysaccharides PCP-B2 and PCP-B3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910268464.3A CN111773237A (en) | 2019-04-03 | 2019-04-03 | Turkey knotweed polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910268464.3A CN111773237A (en) | 2019-04-03 | 2019-04-03 | Turkey knotweed polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111773237A true CN111773237A (en) | 2020-10-16 |
Family
ID=72755647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910268464.3A Pending CN111773237A (en) | 2019-04-03 | 2019-04-03 | Turkey knotweed polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111773237A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626880A (en) * | 2012-08-24 | 2014-03-12 | 复旦大学 | Prunella vulgaris polysaccharide, and preparation method and purpose thereof |
| CN107090048A (en) * | 2016-02-17 | 2017-08-25 | 复旦大学 | Lasiosphaera fenzlii polysaccharide and its purposes in anticomplement medicament is prepared |
-
2019
- 2019-04-03 CN CN201910268464.3A patent/CN111773237A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626880A (en) * | 2012-08-24 | 2014-03-12 | 复旦大学 | Prunella vulgaris polysaccharide, and preparation method and purpose thereof |
| CN107090048A (en) * | 2016-02-17 | 2017-08-25 | 复旦大学 | Lasiosphaera fenzlii polysaccharide and its purposes in anticomplement medicament is prepared |
Non-Patent Citations (2)
| Title |
|---|
| 徐晗;章蕴毅;张建文;陈道峰;: "天然产物中的抗补体活性成分", 中国天然药物, no. 05, 20 September 2007 (2007-09-20), pages 322 - 332 * |
| 沈路路;卢燕;程志红;陈道峰;: "虎杖的抗补体活性蒽醌类成分及其作用靶点", 中草药, no. 18, 28 September 2013 (2013-09-28), pages 2502 - 2507 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hao et al. | Effects of extraction methods on immunology activity and chemical profiles of Lycium barbarum polysaccharides | |
| Zhao et al. | Extraction, characterization and antioxidant activity evaluation of polysaccharides from Smilacina japonica | |
| Chen et al. | Two novel polysaccharides from the torus of Saussurea laniceps protect against AAPH-induced oxidative damage in human erythrocytes | |
| CN110655587B (en) | Preparation method of bletilla striata polysaccharide | |
| Jiang et al. | Preliminary characterization and potential hepatoprotective effect of polysaccharides from Cipangopaludina chinensis | |
| Huang et al. | A pectic polysaccharide from water decoction of Xinjiang Lycium barbarum fruit protects against intestinal endoplasmic reticulum stress | |
| Yin et al. | Isolation, purification, structural analysis and coagulatory activity of water-soluble polysaccharides from Ligustrum lucidum Ait flowers | |
| Gao et al. | Optimisation of enzyme-assisted extraction of Erythronium sibiricum bulb polysaccharide and its effects on immunomodulation | |
| CN109369815B (en) | Wolfberry fruit arabinogalactan and preparation method and application thereof | |
| CN112076207B (en) | High molecular weight cordyceps militaris polysaccharide, preparation method thereof and application of high molecular weight cordyceps militaris polysaccharide in preparation of anticomplement medicines | |
| CN112574326A (en) | Rhizoma gastrodiae macromolecule linear straight-chain glucan and preparation method and application thereof | |
| Cai et al. | Structure, anti-fatigue activity and regulation on gut microflora in vivo of ethanol-fractional polysaccharides from Dendrobium officinale | |
| CN111484565B (en) | Sweet wormwood polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines | |
| CN110498863B (en) | Ficus pumila leaf polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines | |
| CN111773237A (en) | Turkey knotweed polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines | |
| CN109091495B (en) | Application of Glechomae herba polysaccharide in preparing anticomplement medicine and its preparation method | |
| CN101390868B (en) | Plant polysaccharide and preparation method and use thereof | |
| CN111484564B (en) | Spreading hedyotis herb polysaccharide, preparation method thereof and application thereof in preparing anticomplement medicines | |
| CN107456460B (en) | Lithospermum polysaccharide and application thereof in preparation of anticomplement medicines | |
| CN110498864B (en) | Selaginella polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines | |
| CN110498865B (en) | Selaginella maxima polysaccharide, preparation method thereof and application thereof in preparation of anticomplement medicines | |
| Popov et al. | Chemical characterization and anti-inflammatory effect of rauvolfian, a pectic polysaccharide of Rauvolfia callus | |
| CN109234335B (en) | Preparation method of polysaccharide rich in galactofuranose in tabasheer | |
| Biringanine et al. | Partial chemical characterization of immunomodulatory polysaccharides from Plantago palmata Hook. fs leaves | |
| CN115073620B (en) | Two homogeneous blackberry lily polysaccharides with anticomplementary activity and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |